144 related articles for article (PubMed ID: 37738543)
1. Loss of Chromosome 3q Is a Prognostic Marker in Fusion-Negative Rhabdomyosarcoma.
Dehner CA; Bell RC; Cao Y; He K; Chrisinger JSA; Armstrong AE; Yohe M; Shern J; Hirbe AC
JCO Precis Oncol; 2023 Sep; 7():e2300037. PubMed ID: 37738543
[TBL] [Abstract][Full Text] [Related]
2. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Abbou S; Klega K; Tsuji J; Tanhaemami M; Hall D; Barkauskas DA; Krailo MD; Cibulskis C; Nag A; Thorner AR; Pollock S; Imamovic-Tuco A; Shern JF; DuBois SG; Venkatramani R; Hawkins DS; Crompton BD
J Clin Oncol; 2023 May; 41(13):2382-2393. PubMed ID: 36724417
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
Lee JS; Lim SM; Rha SY; Roh JK; Cho YJ; Shin KH; Yang WI; Kim SH; Kim HS
J Clin Pathol; 2014 Jan; 67(1):33-9. PubMed ID: 23922356
[TBL] [Abstract][Full Text] [Related]
5. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells.
Ouchi K; Miyachi M; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Iehara T; Hosoi H
Cancer Cell Int; 2020; 20():192. PubMed ID: 32489328
[TBL] [Abstract][Full Text] [Related]
7. [Comparative genomic hybridization: the profile of chromosomal imbalances in rhabdomyosarcoma].
Li QX; Liu CX; Chun CP; Qi Y; Chang B; Nong WX; Yao ES; Li HA; Li F
Zhonghua Bing Li Xue Za Zhi; 2008 Aug; 37(8):536-41. PubMed ID: 19094465
[TBL] [Abstract][Full Text] [Related]
8. Identify potential driver genes for PAX-FOXO1 fusion-negative rhabdomyosarcoma through frequent gene co-expression network mining.
Zhan X; Liu Y; Jannu AJ; Huang S; Ye B; Wei W; Pandya PH; Ye X; Pollok KE; Renbarger JL; Huang K; Zhang J
Front Oncol; 2023; 13():1080989. PubMed ID: 36793601
[TBL] [Abstract][Full Text] [Related]
9. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation.
Mehra S; de la Roza G; Tull J; Shrimpton A; Valente A; Zhang S
Diagn Mol Pathol; 2008 Mar; 17(1):14-20. PubMed ID: 18303411
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma.
Gasparini P; Casanova M; Villa R; Collini P; Alaggio R; Zin A; Bonvini P; Antonescu CR; Boldrini R; Caserini R; Moro M; Centonze G; Meazza C; Massimino M; Bergamaschi L; Luksch R; Chiaravalli S; Bisogno G; Zaffaroni N; Daidone MG; Sozzi G; Ferrari A
Oncotarget; 2016 Sep; 7(37):58903-58914. PubMed ID: 27385213
[TBL] [Abstract][Full Text] [Related]
11. Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma.
Dehner CA; Armstrong AE; Yohe M; Shern JF; Hirbe AC
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680895
[TBL] [Abstract][Full Text] [Related]
12. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
13. Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation.
Perrone C; Pomella S; Cassandri M; Pezzella M; Giuliani S; Gasperi T; Porrazzo A; Alisi A; Pastore A; Codenotti S; Fanzani A; Barillari G; Conti LA; De Angelis B; Quintarelli C; Mariottini P; Locatelli F; Marampon F; Rota R; Cervelli M
Front Cell Dev Biol; 2023; 11():1061570. PubMed ID: 36755974
[TBL] [Abstract][Full Text] [Related]
14. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
[TBL] [Abstract][Full Text] [Related]
15. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
16. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
[TBL] [Abstract][Full Text] [Related]
17. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study.
Bridge JA; Liu J; Weibolt V; Baker KS; Perry D; Kruger R; Qualman S; Barr F; Sorensen P; Triche T; Suijkerbuijk R
Genes Chromosomes Cancer; 2000 Apr; 27(4):337-44. PubMed ID: 10719362
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Cytogenetic Profiles of Rhabdomyosarcoma with Bone Marrow Involvement in Korean Children: A 15-Year Single-Institution Experience.
Lee DH; Park CJ; Jang S; Cho YU; Seo JJ; Im HJ; Koh KN; Cho KJ; Song JS; Seo EJ
Ann Lab Med; 2018 Mar; 38(2):132-138. PubMed ID: 29214757
[TBL] [Abstract][Full Text] [Related]
19. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
[TBL] [Abstract][Full Text] [Related]
20. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
